Skip to content
PatientMatchFind trials

Screener

Eligibility screening

RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Sponsored by Revolution Medicines, Inc.Study detailsClinicalTrials.gov

5 US sites in MI, TX, VA

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.